Soligenix Inc. Total Liabilities
Soligenix Inc. total liabilities. Based on the latest financial reports, Soligenix Inc. (SNGX) has total liabilities worth $3.85 Million USD as of June 2026. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Check asset resilience ratio of Soligenix Inc. to evaluate the company's liquid asset resilience ratio.
Total Liabilities of Soligenix Inc. (1995–2025)
Total liabilities of Soligenix Inc. from 1995 to 2025. This chart illustrates how Soligenix Inc.'s total liabilities have evolved over time, based on quarterly financial data.
Soligenix Inc. Competitors by Total Liabilities
The table below lists competitors of Soligenix Inc. ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Airway
WAR:AWM
|
Poland | zł20.78 Million |
|
Turbon AG
F:TUR
|
Germany | €15.83 Million |
|
Jenn Feng New Energy Co Ltd
TW:1538
|
Taiwan | NT$127.61 Million |
|
KWESST MICRO SYS.INC.
F:62UA
|
Germany | €4.09 Million |
|
Tempest Therapeutics Inc
NASDAQ:TPST
|
USA | $10.72 Million |
|
Indiana Resources Ltd
AU:IDA
|
Australia | AU$3.34 Million |
|
Bergenbio ASA
OL:BGBIO
|
Norway | Nkr19.75 Million |
|
Caely Holdings Bhd
KLSE:7154
|
Malaysia | RM23.51 Million |
Liability Composition Analysis (1995–2025)
This chart breaks down Soligenix Inc.'s total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the complete balance sheet picture, see how large is Soligenix Inc.'s balance sheet.
Liquidity & Leverage Metrics
Soligenix Inc. Total Liabilities Ratios Explained
Soligenix Inc. total liabilities ratios compare its liabilities with its current assets, cash and shareholder equity.
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 2.77 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.58 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.37 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Soligenix Inc.'s debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Soligenix Inc. (1995–2025)
The table below shows the annual total liabilities of Soligenix Inc. from 1995 to 2025.
| Year | Total Liabilities | Change |
|---|---|---|
| 2025-12-31 | $3.94 Million | -18.67% |
| 2024-12-31 | $4.85 Million | -33.35% |
| 2023-12-31 | $7.27 Million | -56.57% |
| 2022-12-31 | $16.75 Million | +3.74% |
| 2021-12-31 | $16.15 Million | -0.01% |
| 2020-12-31 | $16.15 Million | +155.60% |
| 2019-12-31 | $6.32 Million | +50.02% |
| 2018-12-31 | $4.21 Million | +30.39% |
| 2017-12-31 | $3.23 Million | +12.55% |
| 2016-12-31 | $2.87 Million | -61.25% |
| 2015-12-31 | $7.41 Million | +4.18% |
| 2014-12-31 | $7.11 Million | -29.17% |
| 2013-12-31 | $10.04 Million | +769.61% |
| 2012-12-31 | $1.15 Million | -19.45% |
| 2011-12-31 | $1.43 Million | -25.02% |
| 2010-12-31 | $1.91 Million | +57.91% |
| 2009-12-31 | $1.21 Million | -12.67% |
| 2008-12-31 | $1.39 Million | +16.10% |
| 2007-12-31 | $1.19 Million | -52.55% |
| 2006-12-31 | $2.52 Million | +36.37% |
| 2005-12-31 | $1.84 Million | -11.50% |
| 2004-12-31 | $2.08 Million | +106.90% |
| 2003-12-31 | $1.01 Million | -35.12% |
| 2002-12-31 | $1.55 Million | -88.64% |
| 2001-12-31 | $13.67 Million | +337.69% |
| 2000-12-31 | $3.12 Million | +54.93% |
| 1999-12-31 | $2.02 Million | +34.40% |
| 1998-12-31 | $1.50 Million | +114.29% |
| 1997-12-31 | $700.00K | +438.46% |
| 1996-12-31 | $130.00K | +126.15% |
| 1995-12-31 | $57.48K | -- |
About Soligenix Inc.
Soligenix, Inc., a late-stage biopharmaceutical company, focuses on the development and commercialization of products to treat rare diseases in the United States. The company operates through two segments, Specialized BioTherapeutics and Public Health Solutions. The Specialized BioTherapeutics segment develops SGX301 (HyBryte), a photodynamic therapy, which has completed Phase 3 clinical trial fo… Read more